Answers are grounded in this paper and cite their sources.
Prospective analysis evaluates the effect of tafamidis on 12-month myocardial changes in transthyretin amyloid cardiomyopathy, indicating structural impacts compared to untreated disease course.
Tafamidis improves clinical outcomes in transthyretin amyloid cardiomyopathy (ATTR-CM), yet how tafamidis affects cardiac structure and function remains poorly described. This study prospectively analysed the effect of tafamidis on 12-month longitudinal changes in cardiac structure and function by cardiac magnetic resonance (CMR) compared with the natural course of disease in an untreated historic control cohort.
No takes yet. Share an insight, caveat, or question.
Dobner et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: